Gilead Pipeline Progress Offsets Oncology Sales Slowdown

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.

Gilead at ASH 2024 (Alaric DeArment/Scrip)

While Gilead Sciences has seen softening of sales for its approved oncology products, the company is nevertheless showing momentum in its oncology pipeline, particularly for the CAR-T cell therapy anitocabtagene autoleucel (anito-cel) and the antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy).

Key Takeaways

Gilead reported in its Q1 earnings that sales of key oncology products Trodelvy and Tecartus fell due to factors that included lower demand and competition.

The Foster City, CA-based drug maker announced its first quarter 2025 earnings 24 April. While sales...